

Manuel Nava

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2283837/publications.pdf>

Version: 2024-02-01

17
papers

317
citations

1162367

8
h-index

887659

17
g-index

19
all docs

19
docs citations

19
times ranked

483
citing authors

#	ARTICLE	IF	CITATIONS
1	Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis. International Journal of Molecular Sciences, 2022, 23, 3133.	1.8	8
2	Psycho-Neuro-Endocrine-Immunological Basis of the Placebo Effect: Potential Applications beyond Pain Therapy. International Journal of Molecular Sciences, 2022, 23, 4196.	1.8	4
3	Clinical and Nutritional Implications of Kidney Disease and COVID-19. Current Nutrition and Food Science, 2021, 17, 963-973.	0.3	0
4	Alzheimer's disease and type 2 diabetes mellitus: Pathophysiologic and pharmacotherapeutics links. World Journal of Diabetes, 2021, 12, 745-766.	1.3	28
5	Lipid Accumulation Product Is More Related to Insulin Resistance than the Visceral Adiposity Index in the Maracaibo City Population, Venezuela. Journal of Obesity, 2021, 2021, 1-7.	1.1	4
6	Metabolic Syndrome: Is It Time to Add the Central Nervous System?. Nutrients, 2021, 13, 2254.	1.7	19
7	Advanced Glycation End Products: New Clinical and Molecular Perspectives. International Journal of Environmental Research and Public Health, 2021, 18, 7236.	1.2	23
8	The Role of the Î± Cell in the Pathogenesis of Diabetes: A World beyond the Mirror. International Journal of Molecular Sciences, 2021, 22, 9504.	1.8	13
9	The Sick Adipose Tissue: New Insights Into Defective Signaling and Crosstalk With the Myocardium. Frontiers in Endocrinology, 2021, 12, 735070.	1.5	15
10	Age-specific waist circumference cutoff-points for abdominal obesity diagnosis: a personalized strategy for a large Venezuelan population. Journal of Diabetes and Metabolic Disorders, 2021, 20, 217-227.	0.8	1
11	SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence. Journal of Diabetes Research, 2021, 2021, 1-17.	1.0	1
12	Anti-Aging Effect of Metformin: A Molecular and Therapeutical Perspective. Current Pharmaceutical Design, 2020, 26, 4496-4508.	0.9	18
13	Is "Leptin Resistance" Another Key Resistance to Manage Type 2 Diabetes?. Current Diabetes Reviews, 2020, 16, 733-749.	0.6	8
14	Depression as an Immunometabolic Disorder: Exploring Shared Pharmacotherapeutics with Cardiovascular Disease. Current Neuropharmacology, 2020, 18, 1138-1153.	1.4	10
15	Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines. Advances in Pharmacological Sciences, 2019, 2019, 1-20.	3.7	31
16	Pancreatic Beta Cell Death: Novel Potential Mechanisms in Diabetes Therapy. Journal of Diabetes Research, 2018, 2018, 1-19.	1.0	117
17	Metabolic risk in depression and treatment with selective serotonin reuptake inhibitors: are the metabolic syndrome and an increase in cardiovascular risk unavoidable?. Vessel Plus, 2018, 2, 6.	0.4	10